Wandercraft earns second FDA clearance for Atalante X exoskeleton - The Robot Report

Wandercraft, a French robotics company specializing in self-balancing exoskeletons, has received a second FDA clearance for its Atalante X rehabilitation device, expanding its indications and upgrading its features. This clearance broadens the device's use to individuals with spinal cord injuries (SCI) from levels C4 to L5 and those with multiple sclerosis (MS), enabling hands-free gait therapy for a wider range of patients. The Atalante X uses AI-driven self-balancing technology to support lower limb, posture, balance, and upper limb reinforcement exercises in an upright position, allowing therapists to personalize training down to the joint level, even for patients with severely limited upper-body strength. The FDA’s decision was supported by a multicenter study involving 547 training sessions with patients having high-level SCI, which demonstrated the device’s safety and potential functional benefits, particularly for tetraplegic patients. The upgraded Atalante X now features joint-specific assistance control, step-length adjustments, enhanced patient data